



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

Mail Stop: 3561

May 15, 2017

Via E-mail

Julie Eastland  
Chief Financial Officer  
Cascadian Therapeutics, Inc.  
2601 Fourth Ave., Suite 500  
Seattle, Washington 98121

**Re: Cascadian Therapeutics, Inc.  
Registration Statement on Form S-3  
Filed May 8, 2017  
File No. 333-217773**

Dear Ms. Eastland:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Ruairi J. Regan, Staff Attorney, at (202) 551-3269 with any questions.

Sincerely,

/s/ James Lopez (for)

John Reynolds  
Assistant Director  
Office of Beverages,  
Apparel and Mining

cc: Alan Smith, Esq.  
Fenwick & West LLP